☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Indivior
PharmaShots Weekly Snapshots (October 09–13, 2023) _
October 14, 2023
Indivior Entered into an Exclusive License Agreement with Alar to Develop and Commercialise ALA-1000 and Future Buprenorphine-Base...
October 13, 2023
Indivior’s Opvee (nalmefene) Nasal Spray Receives the US FDA’s Approval for Treatment of Opioid Overdose
May 22, 2023
Indivior to Acquire Opiant Pharmaceuticals for ~$145M
November 14, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.
